This database contains 163 studies, archived under the term: "Other"
Click here to filter this large number of results.
A multi-center randomized proof-of-concept clinical trial applying ¹⁸FFDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease
Tzimopoulou, Sofia,
Cunningham, Vincent J.,
Nichols, Thomas E.,
Searle, Graham,
Bird, Nick P.,
Mistry, Prafull,
Dixon, Ian J.,
Hallett, William A.,
Whitcher, Brandon,
Brown, Andrew P.,
Zvartau-Hind, Marina,
Lotay, Narinder,
Lai, Robert Y. K.,
Castiglia, Mary,
Jeter, Barbara,
Matthews, Julian C.,
Chen, Kewei,
Bandy, Dan,
Reiman, Eric M.,
Gold, Michael,
Rabiner, Eugenii A.,
Matthews, Paul M.
Here we report the first multi-center clinical trial in Alzheimer’s disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months treatment with the PPARγ agonist Rosiglitazone XR versus placebo in 80 mild to moderate AD patients. Secondary objectives included testing for reduction […]
Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers
Serrano-Pozo, Alberto,
Vega, Gloria L.,
Lütjohann, Dieter,
Locascio, Joseph J.,
Tennis, Marsha K.,
Deng, Amy,
Atri, Alireza,
Hyman, Bradley T.,
Irizarry, Michael C.,
Growdon, John H.
Preclinical and epidemiologic studies suggest a protective effect of statins on Alzheimer disease (AD). Experimental evidence indicates that some statins can cross the blood-brain barrier, alter brain cholesterol metabolism, and may ultimately decrease the production of amyloid-beta (Abeta) peptide. Despite these promising leads, clinical trials have yielded inconsistent results regarding the benefits of statin treatment […]
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, Tomohiko,
Hanyu, Haruo,
Hirao, Kentaro,
Kanetaka, Hidekazu,
Sakurai, Hirofumi,
Iwamoto, Toshihiko
To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus. We randomly assigned 42 patients to either the group treated with 15-30 […]
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M.,
Bell, K. L.,
Galasko, D.,
Galvin, J. E.,
Thomas, R. G.,
van Dyck, C. H.,
Aisen, P. S.
Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Keren, R.,
Porsteinsson, A. P.,
van Dyck, C. H.,
Tariot, P. N.,
Gilman, S.,
Arnold, D.,
Abushakra, S.,
Hernandez, C.,
Crans, G.,
Liang, E.,
Quinn, G.,
Bairu, M.,
Pastrak, A.,
Cedarbaum, J. M.
Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).; Methods: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the […]
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial
Sato, Yoshihiro,
Honda, Yoshiaki,
Umeno, Kazuo,
Hayashida, Norimasa,
Iwamoto, Jun,
Takeda, Tsuyoshi,
Matsumoto, Hideo
A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that vitamin K deficiency and low 25-hydroxyvitamin D (25-OHD) with compensatory hyperparathyroidism cause reduced bone mineral density (BMD) in female patients with AD. This may […]
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies
Harrington, C.,
Sawchak, S.,
Chiang, C.,
Davies, J.,
Donovan, C.,
Saunders, A. M.,
Irizarry, M.,
Jeter, B.,
Zvartau-Hind, M.,
van Dyck, C. H.,
Gold, M.
Introduction: Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to any AChEI). An open-label extension study (REFLECT-4) assessed RSG XR long-term safety.; […]